TY - JOUR
T1 - Two or six hyperthermia treatments as an adjunct to radiation therapy yield similar tumor responses
T2 - results of a randomized trial
AU - Kapp, Daniel S.
AU - Petersen, Ivy A.
AU - Cox, Richard S.
AU - Hahn, George M.
AU - Fessenden, Peter
AU - Prionas, Stavros D.
AU - Lee, Eric R.
AU - Meyer, John L.
AU - Samulski, Thaddeus V.
AU - Bagshaw, Malcolm A.
N1 - Funding Information:
in the data analyses, and Sharon Clarke for preparing this manuscript. Particular thanks is extended to all the referring physicians and to the patients, for without their support and cooperation, this trial could not have been performed. Supported by NC1 grant CA-44665. Accepted for publication 2 1 June 1990.
PY - 1990/12
Y1 - 1990/12
N2 - From March 1984 to February 1988, 70 patients with 179 separate treatment fields containing superficially located (<3 cm from surface) recurrent or metastatic malignancies were stratified based on tumor size, histology, and prior radiation therapy and enrolled in prospective randomized trials comparing two versus six hyperthermia treatments as an adjunct to standardized courses of radiation therapy. A total of 165 fields completed the combined hyperthermia-radiation therapy protocols and were evaluable for response. No statistically significant differences were observed between the two treatment arms with respect to tumor location; histology; initial tumor volume; patient age and pretreatment performance status; extent of prior radiation therapy, chemotherapy, hormonal therapy, or immunotherapy; or concurrent radiation therapy. The means for all fields of the averaged minimum, maximum, and average measured intratumoral temperatures were 40.2°C, 44.8°C, 42.5°C, respectively, and did not differ significantly between the fields randomized to two or six hyperthermia treatments. The treatment was well tolerated with an acceptable level of complications. At 3 weeks after completion of therapy, complete disappearance of all measurable tumor was noted in 52% of the fields, ≥50% tumor reduction was noted in 7% of the fields, <50% tumor reduction was noted in 21% of the fields, and continuing regression (monotonic regression to <50% of initial volume) was noted in 20% of the fields. No significant differences were noted in tumor responses at 3 weeks for fields randomized to two versus six hyperthermia treatments (p = 0.89). Cox regression analyses were performed to identify pretreatment or treatment parameters that correlated with duration of local control. Tumor histology, concurrent radiation dose, and tumor volume all correlated with duration of local control. The mean of the minimum intratumoral temperatures (<41°C vs. ≥41°C) was of borderline prognostic significance in the univariate analysis, and added to the power of the best three covariate model. Neither the actual number of hyperthermia treatments administered nor the hyperthermia protocol group (two versus six treatments) correlated with duration of local control. The development of thermotolerance is postulated to be, at least in part, responsible for limiting the effectiveness of multiple closely spaced hyperthermia treatments.
AB - From March 1984 to February 1988, 70 patients with 179 separate treatment fields containing superficially located (<3 cm from surface) recurrent or metastatic malignancies were stratified based on tumor size, histology, and prior radiation therapy and enrolled in prospective randomized trials comparing two versus six hyperthermia treatments as an adjunct to standardized courses of radiation therapy. A total of 165 fields completed the combined hyperthermia-radiation therapy protocols and were evaluable for response. No statistically significant differences were observed between the two treatment arms with respect to tumor location; histology; initial tumor volume; patient age and pretreatment performance status; extent of prior radiation therapy, chemotherapy, hormonal therapy, or immunotherapy; or concurrent radiation therapy. The means for all fields of the averaged minimum, maximum, and average measured intratumoral temperatures were 40.2°C, 44.8°C, 42.5°C, respectively, and did not differ significantly between the fields randomized to two or six hyperthermia treatments. The treatment was well tolerated with an acceptable level of complications. At 3 weeks after completion of therapy, complete disappearance of all measurable tumor was noted in 52% of the fields, ≥50% tumor reduction was noted in 7% of the fields, <50% tumor reduction was noted in 21% of the fields, and continuing regression (monotonic regression to <50% of initial volume) was noted in 20% of the fields. No significant differences were noted in tumor responses at 3 weeks for fields randomized to two versus six hyperthermia treatments (p = 0.89). Cox regression analyses were performed to identify pretreatment or treatment parameters that correlated with duration of local control. Tumor histology, concurrent radiation dose, and tumor volume all correlated with duration of local control. The mean of the minimum intratumoral temperatures (<41°C vs. ≥41°C) was of borderline prognostic significance in the univariate analysis, and added to the power of the best three covariate model. Neither the actual number of hyperthermia treatments administered nor the hyperthermia protocol group (two versus six treatments) correlated with duration of local control. The development of thermotolerance is postulated to be, at least in part, responsible for limiting the effectiveness of multiple closely spaced hyperthermia treatments.
KW - Complications
KW - Hyperthermia
KW - Local control
KW - Number of treatments
KW - Prognostic parameters
KW - Superficial lesions
KW - Thermotolerance
UR - http://www.scopus.com/inward/record.url?scp=0025614223&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025614223&partnerID=8YFLogxK
U2 - 10.1016/0360-3016(90)90361-M
DO - 10.1016/0360-3016(90)90361-M
M3 - Article
C2 - 2262371
AN - SCOPUS:0025614223
SN - 0360-3016
VL - 19
SP - 1481
EP - 1495
JO - International journal of radiation oncology, biology, physics
JF - International journal of radiation oncology, biology, physics
IS - 6
ER -